- Home
- PRTA
as 07-26-2024 4:00pm EST
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
Upcoming Earnings Alert:
Get ready for potential market movements as Prothena Corporation plc PRTA prepares to release earnings report on 01 Aug 2024.
| Founded: | 2012 | Country: | Ireland |
| Employees: | N/A | City: | DUBLIN 2 |
| Market Cap: | 1.2B | IPO Year: | N/A |
| Target Price: | $62.50 | AVG Volume (30 days): | 470.1K |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.25 | EPS Growth: | N/A |
| 52 Week Low/High: | $18.69 - $70.09 | Next Earning Date: | 08-01-2024 |
| Revenue: | $89,251,000 | Revenue Growth: | 62.51% |
| Revenue Growth (this year): | -83.16% | Revenue Growth (next year): | 484.92% |
Stock Insider Trading Activity of Prothena Corporation plc (PRTA)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Walker Karin L | PRTA | Chief Accounting Officer | Jan 24 '24 | Sell | $34.00 | 5,000 | $170,000.00 | 0 | SEC Form 4 |
| Walker Karin L | PRTA | Chief Accounting Officer | Dec 20 '23 | Sell | $36.68 | 1,678 | $61,543.17 | 3,322 | SEC Form 4 |
| Walker Karin L | PRTA | Chief Accounting Officer | Dec 20 '23 | Sell | $37.45 | 3,322 | $124,408.57 | 0 | SEC Form 4 |
| Walker Karin L | PRTA | Chief Accounting Officer | Nov 30 '23 | Sell | $34.00 | 5,000 | $170,000.00 | 0 | SEC Form 4 |
| Walker Karin L | PRTA | Chief Accounting Officer | Oct 25 '23 | Sell | $40.27 | 1,789 | $72,043.21 | 3,211 | SEC Form 4 |
| Walker Karin L | PRTA | Chief Accounting Officer | Oct 25 '23 | Sell | $41.38 | 2,917 | $120,718.00 | 294 | SEC Form 4 |
| Walker Karin L | PRTA | Chief Accounting Officer | Oct 25 '23 | Sell | $42.28 | 294 | $12,430.11 | 0 | SEC Form 4 |
Latest Prothena Corporation plc News
PRTA Breaking Stock News: Dive into PRTA Ticker-Specific Updates for Smart Investing
Zacks
a day ago
Prothena (PRTA) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Zacks
11 days ago
Legend Biotech (LEGN) Surges 12.1%: Is This an Indication of Further Gains?
Zacks
a month ago
Prothena (PRTA) Moves 9.3% Higher: Will This Strength Last?
Simply Wall St.
a month ago
Here's Why We're Not Too Worried About Prothena's (NASDAQ:PRTA) Cash Burn Situation
Zacks
a month ago
The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune (Revised)
Zacks
a month ago
The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune
Investor's Business Daily
a month ago
Eli Lilly Seesaws On FDA Win, And Pushes Alzheimer's Stocks Prothena, Eisai Lower
Zacks
a month ago
Eli Lilly (LLY) Alzheimer's Drug Donanemab Gets FDA Panel Nod
Compare PRTA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PRTA Prothena Corporation plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.